Abrégé

The present invention relates to a nucleic acid molecule encoding an RNA-guided DNA endonuclease, which is (a) a nucleic acid molecule encoding the RNA-guided DNA endonuclease comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 3; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2 or 4; (c) a nucleic acid molecule encoding a RNA-guided DNA endonuclease the amino acid sequence of which is at least 70 % identical to the amino acid sequence of (a); preferably at least 80 % identical, more preferably at least 90 % identical, and most preferred at least 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 70 % identical to the nucleotide sequence of (b), preferably at least 80 % identical, more preferably at least 90 % identical, and most preferred at least 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 15/55 - Hydrolases (3)
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The present invention relates to a process for the preparation of a fermentable sugar composition, wherein a polysaccharide composition is treated by at least one glucoamylase enzyme and at least one oligo-1,6-glucosidase enzyme, and wherein the fermentable sugars are removed during the process. Thereby, the otherwise non-fermentable sugars can be utilized in the fermentation process to yield a fermentation product such as an alcohol or an organic acid or amino acid.

Classes IPC  ?

• C12P 7/06 - Éthanol en tant que produit chimique et non en tant que boisson alcoolique
• C12P 19/12 - Disaccharides
• C12P 19/16 - Préparation de composés contenant des radicaux saccharide préparés par action d'une alpha-1, 6 glucosidase, p. ex. amylose, amylopectine déramifiée
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

The present invention relates to a method of producing a 10-hydroxy fatty acid, wherein the method comprises contacting a sample comprising a (9Z) or (9E)-fatty acid with a polypeptide having the activity of an oleate hydratase (EC 4.2,1.53) encoded by a nucleic acid molecule, wherein the nucleic acid molecule is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 7; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2 or 8; (c) a nucleic acid molecule comprising or consisting of a nucleic acid molecule encoding a polypeptide having the activity of an oleate hydratase the amino acid sequence of which is at least 91% identical to the amino acid sequence of SEQ ID NO: 1 or 7; (d) a nucleic acid molecule encoding a polypeptide having the activity of an oleate hydratase and comprising or consisting of a nucleotide sequence which is at least 91 % identical to the nucleotide sequence of SEQ ID NO: 2 or 8; (e) a fragment of the nucleic acid molecule of any of (a) to (d) comprising at least 1341 nucleotides and encoding a polypeptide having the activity of an oleate hydratase; or (f) the nucleic acid sequence of any of (a) to (d) wherein T is U.

Classes IPC  ?

• C12N 9/88 - Lyases (4.)
• C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées

Abrégé

( LRRC8A ), LRRC8B, LRRC8C, LRRC8D LRRC8E( LRRC8A ), LRRC8B, LRRC8C, LRRC8DLRRC8E( LRRC8A ), LRRC8B, LRRC8C, LRRC8DLRRC8ELRRC8A, LRRC8B, LRRC8C,LRRC8A, LRRC8B, LRRC8C, LRRC8D or LRRC8E gene or the innexin gene is knocked- out, and (ii) enriching cells, wherein the gene of interest is genome edited.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur

Abrégé

The present invention relates to the leucine-rich repeat-containing protein 8A (LRRC8A), and/or an activator of LRRC8A, for use in the treatment and/or prevention of a skin condition associated with an altered differentiation of keratinocytes. Preferably, the skin condition associated with an altered differentiation of keratinocytes is psoriasis or dermatitis, preferably atopic dermatitis. The present invention further relates to a method of identifying a compound capable of altering the differentiation of keratinocytes, the method comprising the steps of (a) contacting keratinocytes with a test compound and determining the amount of LRRC8A protein or LRRC8A transcript in said keratinocytes; and (b) comparing the amount of LRRC8A protein or LRRC8A transcript determined in step (a) with the amount of LRRC8A protein or LRRC8A transcript in a control not contacted with said test compound, wherein a change in the amount of LRRC8A protein or LRRC8A transcript after contacting the keratinocytes with the test compound indicates that the test compound is capable of altering the differentiation of keratinocytes. Furthermore, the present invention relates to a method of identifying a compound capable of altering the differentiation of keratinocytes, the method comprising the steps of (a) contacting keratinocytes with a test compound and determining the activity of (a) VRAC(s) comprising LRRC8A in said keratinocytes; and (b) comparing the activity determined in step (a) with the activity in a control not contacted with said test compound, wherein a change in the activity of (a) VRAC(s) comprising LRRC8A after contacting the keratinocytes with the test compound indicates that the test compound is capable of altering the differentiation of keratinocytes. The present invention further relates to an inhibitor of the leucine-rich repeat-containing protein 8A (LRRC8A) for use in the treatment and/or prevention of a skin condition selected from skin injury and impaired wound healing, as well as to a cosmetic method for alleviating the effects of a skin condition on the appearance of the skin of an affected individual, the method comprising topically administering an effective amount of (i) leucine-rich repeat-containing protein 8A (LRRC8A); (ii) an activator of LRRC8A; (iii) LRRC8A and an activator of LRRC8A; or (iv) an inhibitor of LRRC8A.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
• A61P 17/06 - Antipsoriasiques
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80% identical to the amino acid sequence of (a), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80% identical to the nucleotide sequence of (b), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

Classes IPC  ?

• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61K 38/43 - EnzymesProenzymesLeurs dérivés
• C12P 21/00 - Préparation de peptides ou de protéines
• C12N 15/57 - Hydrolases (3) agissant sur les liaisons peptidiques (3.4)
• C12N 9/50 - Protéinases
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

The present invention relates to a method for the recombinant production of a serine protease comprising (a) culturing a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; or (a') culturing a host cell the genome of which encodes in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, and wherein the coding sequences of the serine protease and/or the proteinaceous inhibitor have been introduced into the host cell genome by applying a CRISPR technology, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; and (b) isolating the serine protease expressed in step (a) or (a') from the host cell. The present invention also relates to a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form a serine protease and a proteinaceous inhibitor of the serine protease.

Classes IPC  ?

• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
• C07K 14/81 - Inhibiteurs de protéase
• C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
• C12N 15/67 - Méthodes générales pour favoriser l'expression
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

The invention provides a process of isolating or enriching a heavy metal present in a liquid medium. The process comprising the following steps: (a) incubating a suspension containing (i) particulate scrap metal, household waste and/or industrial waste containing a heavy metal in elemental form and (ii) biomass comprising a bacterium, or a combination of two or more bacteria, capable of binding the heavy metal; (b) separating the biomass having bound heavy metal from the suspension of step (a); and (c) isolating the heavy metal from the biomass separated in step (b).

Classes IPC  ?

• C22B 3/24 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p. ex. par extraction avec des résines solides
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 1/22 - Procédés utilisant de la cellulose ou ses hydrolysats ou milieux de culture en contenant
• C12N 1/34 - Procédés utilisant la culture en mousse
• C22B 3/18 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés à l'aide de micro-organismes ou d'enzymes, p. ex. de bactéries ou d'algues
• C22B 3/00 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés

Abrégé

The present invention relates to compositions of perillic acid compounds and activity enhancing substances, therapeutic and non-therapeutic uses of the compositions as well as a method of preparing the compositions.

Classes IPC  ?

• A61K 8/34 - Alcools
• A61K 8/36 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 8/368 - Acides carboxyliquesLeurs sels ou anhydrides dans lesquels le groupe carboxyle est directement lié aux atomes de carbone du cycle aromatique
• A61Q 19/00 - Préparations pour les soins de la peau
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque

Abrégé

The present invention relates to compositions of perillic acid compounds, therapeutic and non-therapeutic uses of the compounds and compositions as well as a method of preparing the composition.

Classes IPC  ?

• A61K 8/36 - Acides carboxyliquesLeurs sels ou anhydrides
• A61Q 19/00 - Préparations pour les soins de la peau
• A61K 8/06 - Émulsions
• A61K 31/015 - Hydrocarbures carbocycliques

Abrégé

The invention relates to a preparation containing (a) at least one NSAID active ingredient and (b) dehydroabietic acid or an extract containing dehydroabietic acid, as a drug.

Classes IPC  ?

• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test tool into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.

Classes IPC  ?

• C22B 3/24 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p. ex. par extraction avec des résines solides
• C12R 1/00 - Micro-organismes

Abrégé

The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test too! into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.

Classes IPC  ?

• C22B 3/24 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p. ex. par extraction avec des résines solides
• C12R 1/00 - Micro-organismes

Abrégé

Accordingly, the present invention relates to a nucleic acid molecule encoding a protein capable of forming a calcium-activated chloride channel, wherein said nucleic acid molecule comprises or consists of (a) a nucleic acid molecule encoding a protein having the amino acid sequence of SEQ ID NO:1; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO:2; (c) a nucleic acid molecule having the sequence of SEQ ID NO:2, wherein each thymine is replaced by uracil; (d) a nucleic acid molecule that hybridizes under stringent conditions to the complementary strand of a nucleic acid molecule of (a), (b) or (c); (e) a nucleic acid molecule encoding a protein having at least 97% sequence identity to the protein of (a); or (f) a nucleic acid molecule that is degenerate with respect to the nucleic acid molecule of (b), (c) or (d). The present invention further relates to a protein capable of forming a calcium-activated chloride channel, the use of the nucleic acid molecule of or the protein of the invention for identifying an inhibitor of sweat formation as well as an in vitro method of identifying an inhibitor of sweat formation.

Classes IPC  ?

• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

The present invention relates to proliferating human taste cells, wherein the cells are the cells deposited under the DSMZ deposit accession number DSM ACC3169 or taste cells derived thereof. The present invention further relates to the proliferating human taste cells of the invention for use in research. Further, the present invention relates to in vitro methods for analyzing the signalling response of taste cells to a molecule involved in taste signalling, in vitro methods of identifying agents capable of eliciting a taste response in taste cells as well as in vitro methods of identifying modulators of taste signalling.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/0793 - Neurones

Abrégé

A process of isolating a REE or a group of REE from a solution or dispersion containing said REE or said group of REEs comprising the following steps: (i) preparing a mixture comprising said solution or dispersion and biomass comprising at least one organism selected from any one of the following organism classes: eubacteria, archaea, algae, and fungi, whereby the at least one organism is capable of adsorbing or accumulating said REE or said group of REEs; (ii) incubating said mixture of step (i) for allowing the adsorption or accumulation of said REE or said group of REEs by said biomass; (iii) separating the biomass having adsorbed or accumulated REE(s) from the mixture of step (ii); and (iv) isolating said REE or said group of REEs from said biomass separated in step (iii).

Classes IPC  ?

• C22B 3/18 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés à l'aide de micro-organismes ou d'enzymes, p. ex. de bactéries ou d'algues
• C22B 59/00 - Obtention des métaux des terres rares

Abrégé

A process of isolating a REE or a group of REE from a solution or dispersion containing said REE or said group of REEs comprising the following steps: (i) preparing a mixture comprising said solution or dispersion and biomass comprising at least one organism selected from any one of the following organism classes: eubacteria, archaea, algae, and fungi, whereby the at least one organism is capable of adsorbing or accumulating said REE or said group of REEs; (ii) incubating said mixture of step (i) for allowing the adsorption or accumulation of said REE or said group of REEs by said biomass; (iii) separating the biomass having adsorbed or accumulated REE(s) from the mixture of step (ii); and (iv) isolating said REE or said group of REEs from said biomass separated in step (iii).

Classes IPC  ?

• C22B 3/18 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés à l'aide de micro-organismes ou d'enzymes, p. ex. de bactéries ou d'algues
• C22B 59/00 - Obtention des métaux des terres rares

Abrégé

Accordingly, the present invention relates to a nucleic acid molecule encoding a protein capable of forming a calcium-activated chloride channel, wherein said nucleic acid molecule comprises or consists of (a) a nucleic acid molecule encoding a protein having the amino acid sequence of SEQ ID NO:1; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO:2; (c) a nucleic acid molecule having the sequence of SEQ ID NO:2, wherein each thymine is replaced by uracil; (d) a nucleic acid molecule that hybridizes under stringent conditions to the complementary strand of a nucleic acid molecule of (a), (b) or (c); (e) a nucleic acid molecule encoding a protein having at least 97% sequence identity to the protein of (a); or (f) a nucleic acid molecule that is degenerate with respect to the nucleic acid molecule of (b), (c) or (d). The present invention further relates to a protein capable of forming a calcium-activated chloride channel, the use of the nucleic acid molecule of or the protein of the invention for identifying an inhibitor of sweat formation as well as an in vitro method of identifying an inhibitor of sweat formation.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

The present invention relates to proliferating human taste cells, wherein the cells are the cells deposited under the DSMZ deposit accession number DSM ACC3169 or taste cells derived thereof. The present invention further relates to the proliferating human taste cells of the invention for use in research. Further, the present invention relates to in vitro methods for analysing the signalling response of taste cells to a molecule involved in taste signalling, in vitro methods of identifying agents capable of eliciting a taste response in taste cells as well as in vitro methods of identifying modulators of taste signalling.

Classes IPC  ?

• C12N 5/079 - Cellules neurales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/0793 - Neurones

Abrégé

The present invention relates to a host cell having an elevated expression or activity of an enzyme as compared with the parent cell from which it has been derived, said enzyme having lactoyl-CoA reductase activity. Furthermore, provided is a method of producing lactaldehyde and/or 1,2-propanediol, said method comprising culturing said host cell and/or utilizing said enzyme to produce said compound.

Classes IPC  ?

• C12P 7/18 - Polyols
• C12P 7/24 - Préparation de composés organiques contenant de l'oxygène contenant un groupe carbonyle
• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/10 - Transférases (2.)
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices,and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.

Classes IPC  ?

• A61K 31/235 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
• A61K 8/00 - Cosmétiques ou préparations similaires pour la toilette
• A61Q 19/00 - Préparations pour les soins de la peau
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A23L 1/00 - Aliments ou produits alimentaires; Leur préparation ou traitement (leur conservation en général A23L 3/00)
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.

Classes IPC  ?

• A61K 8/41 - Amines
• A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p. ex. dentifricesBains de bouche
• A61Q 17/02 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes contenant des produits insecticides
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

The invention relates to a nucleic acid molecule encoding a polypeptide having the activity of a catalase (EC 1.1 1.1.6), which nucleic acid molecule is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule comprising or consisting of a nucleic acid molecule encoding a polypeptide having the activity of a catalase the amino acid sequence of which is at least 99% identical to the amino acid sequence of SEQ ID NO: 1, (d) a nucleic acid molecule encoding a polypeptide having the activity of a catalase and comprising or consisting of a nucleotide sequence which is at least 98% identical to the nucleotide sequence of SEQ ID NO: 2, (e) a fragment of the polypeptide of any of (a) to (d) having the activity of a catalase and comprising at least 675 amino acids; or (f) the nucleic acid sequence of any of (a) to (d) wherein T is U.

Classes IPC  ?

• A61K 8/66 - Enzymes
• A61K 38/44 - Oxydoréductases (1)
• A61L 12/08 - Procédés ou appareils pour la désinfection ou la stérilisation des lentilles de contactAccessoires à cet effet utilisant des substances chimiques
• A61Q 19/08 - Préparations contre le vieillissement
• C11D 3/386 - Préparations contenant des enzymes
• C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)

Abrégé

Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80% identical to the amino acid sequence of (a), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80% identical to the nucleotide sequence of (b), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

Classes IPC  ?

• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
• C12N 9/50 - Protéinases
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• C12N 15/57 - Hydrolases (3) agissant sur les liaisons peptidiques (3.4)
• C12P 21/00 - Préparation de peptides ou de protéines
• A61K 38/43 - EnzymesProenzymesLeurs dérivés
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

The present invention relates to a nucleic acid molecule encoding a polypeptide having cytochrome P450 monooxygenase activity, wherein said polypeptide comprises a reductase domain that deviates by at least one mutation from (a) the reductase domain of cytochrome P450 BM3, wherein the reductase domain of cytochrome P450 BM3 is represented by SEQ ID NO: 1; or (b) a reductase domain having at least 95% sequence identity to SEQ ID NO:1; and wherein said mutation(s) result(s) in an increased cytochrome P450 monooxygenase activity as compared to a polypeptide comprising the reductase domain of SEQ ID NO: 1. The present invention also relates to a vector comprising the nucleic acid molecule of the invention and a host transformed with the vector. Furthermore, the invention relates to a method of producing a polypeptide comprising culturing the host of the invention as well as to a polypeptide encoded by the nucleic acid molecule of the invention or produced by the method of the invention. The present invention further relates to the use of the polypeptide of the invention in biotransformation or fine chemical synthesis, to an oligo- or polynucleotide which specifically hybridizes to the nucleic acid molecule of the invention as well as to a composition and to a kit.

Classes IPC  ?

• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase

Abrégé

The present invention relates to a novel nucleic acid molecule encoding (I) a polypeptide having the activity of a glucose oxidase (EC 1.1.3.4); or (II) a fragment of the polypeptide of (I) having the activity of a glucose oxidase and comprising at least 400 amino acids. Moreover, the invention relates to a vector encoding the nucleic acid molecule, a host cell transformed, transduced or transfected with the vector, a the protein encoded by the nucleic acid molecule, and compositions comprising said nucleic acid molecule, vector, host cell, protein or combinations thereof.

Classes IPC  ?

• C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)

Abrégé

The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein. The chimeric protein may only consist of the above mentioned core of (a) and (b), but may also be flanked by additional components of the core, i.e. (a) or (b) or by (an) additional complete core(s) (a) and (b). The present invention furthermore relates to a method of coating and/or impregnating a material, comprising contacting the material with the chimeric protein or the composition of the invention.

Classes IPC  ?

• C07K 14/37 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de champignons
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• C09D 189/00 - Compositions de revêtement à base de protéinesCompositions de revêtement à base de leurs dérivés

Abrégé

The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12P 21/00 - Préparation de peptides ou de protéines

Abrégé

We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80 % identical to the amino acid sequence of (a), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80 % identical to the nucleotide sequence of (b), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

Classes IPC  ?

• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61K 38/43 - EnzymesProenzymesLeurs dérivés
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serineprotease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprisingor consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80 % identical to the amino acid sequence of (a), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80 % identical to the nucleotide sequenceof (b), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

Classes IPC  ?

• A61K 38/43 - EnzymesProenzymesLeurs dérivés
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present invention relates to a cyanide-free process of isolating precious metal gold from a particulate material containing said metal, comprising the following steps of (i) preparing an aqueous mixture containing said particulate material and biomass comprising having an S-LAYER or archaea having an S-LAYER; eubacteria and archaea, algae, and fungi; said biomass being capable of adsorbing said metal; (ii) incubating said aqueous mixture of step (i) for allowing binding of said metal to said biomass; (iii) separating the biomass having bound metal from the aqueous mixture of step (ii); and (iv) isolating the metal from said biomass separated in step (iii).

Classes IPC  ?

• C22B 11/00 - Obtention des métaux nobles
• C22B 3/18 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés à l'aide de micro-organismes ou d'enzymes, p. ex. de bactéries ou d'algues

Abrégé

The present invention relates to a cyanide-free process of isolating precious metal gold from a particulate material containing said metal, comprising the following steps of (i)prepar-ing an aqueous mixture containing said particulate material and biomass comprising having an S--LAYER or archaea having an S-LAYER; eubacte-ria and archaea, algae, and fungi; said biomass be-ing capable of adsorbing said metal; (ii) incubating said aqueous mixture of step (i) for allowing bind-ing of said metal to said biomass; (iii) separating the biomass having bound metal from the aqueous mixture of step (ii); and (iv) isolating the metal from said biomass separated in step (iii).

Classes IPC  ?

• C22B 3/18 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés à l'aide de micro-organismes ou d'enzymes, p. ex. de bactéries ou d'algues
• C22B 11/00 - Obtention des métaux nobles